One can predict the potential therapeutic effectiveness of a particular TGF-β inhibitor in conjunction with a conventional therapeutic by surveying the impact of the conventional therapeutic alone on the activation of a TGF-β gene expression signature within the tumor. The gene discussed is TGFB1; the disease is neoplasm.